Authored by James Sheppard
The world renowned Karolinska Institutet has partnered with the Cambridge based biotech Moderna Therapeutics to develop new messenger RNA therapeutics for a range of serious diseases.
The partnership will see the establishment of a new company called Moderna Therapeutics Sweden, based in Stockholm. This venture is Moderna’s first expansion outside of the US. The partnership will focus on the discovery and development of innovative drugs using Moderna’s messenger RNA (mRNA) Therapeutics technology. mRNA Therapeutics enable the in vivo production of both intracellular proteins and secreted proteins. As a result, Moderna’s platform has the potential to speed the development and manufacture of treatments for many diseases that are currently untreatable with existing pharmaceutical approaches.
Under the terms of the partnership, Moderna will sponsor research grants for scientists at both institutions to conduct preclinical research with novel mRNA Therapeutics™. As this pre-clinical work is successfully completed, Moderna will conduct clinical trials of new drug candidates at Karolinska University Hospital.
Stéphane Bancel, President and founding CEO of Moderna said ‘Moderna is investing heavily to bring mRNA Therapeutics to patients, and our science is accelerating rapidly. This partnership puts our mRNA Therapeutics platform in the hands of Karolinska’s world-class scientists and clinical researchers to develop new drugs and therapeutic approaches that cannot be done with small molecules or biologics – bringing new hope to patients with serious diseases.’